<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        53-116-99
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CURAM 312.5 MG-5ML POWDER FOR SUSP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMOXICILLIN,CLAVULANIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250,62.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANDOZ" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Curam 312.5 mg/5 ml is an antibiotic and works by killing bacteria that cause infections. It contains two different medicines called amoxicillin and clavulanic acid. Amoxicillin belongs to a group of medicines called &ldquo;penicillins&rdquo; that can sometimes be stopped from working (made inactive). The other active component (clavulanic acid) stops this from happening.</p><p>Curam 312.5 mg/5 ml is used in adults and children to treat the following infections:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; middle ear and sinus infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin and soft tissue infections including dental infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone and joint infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not give your child Curam 312.5 mg/5 ml:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are allergic to amoxicillin, clavulanic acid, penicillin or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have ever had a severe allergic reaction to any other antibiotic. This can include a skin rash or swelling of the face or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have ever had liver problems or jaundice (yellowing of the skin) when taking an antibiotic.</p><p>&nbsp;</p><p><strong>Do not give Curam 312.5 mg/5 ml to your child if any of the above apply to your child. </strong>If you are not sure, talk to your doctor or pharmacist before giving Curam 312.5 mg/5 ml.</p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist before giving your child this medicine if they:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have glandular fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are being treated for liver or kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are not passing water regularly.</p><p>If you are not sure if any of the above apply to your child, talk to their doctor or pharmacist before giving Curam 312.5 mg/5 ml.</p><p>In some cases, your doctor may investigate the type of bacteria that is causing your child&rsquo;s infection. Depending on the results, your child may be given a different strength of Curam 312.5 mg/5 ml or a different medicine.</p><p><strong>Conditions you need to look out for</strong></p><p>Curam 312.5 mg/5 ml can make some existing conditions worse, or cause serious side effects. These include allergic reactions, convulsions (fits) and inflammation of the large intestine. You must look out for certain symptoms while your child is taking Curam 312.5 mg/5 ml, to reduce the risk of any problems. See &lsquo;<em>Conditions you need to look out for&rsquo; </em>in <strong>Section 4</strong>.</p><p><strong>Blood and urine tests</strong></p><p>If your child is having blood tests (such as red blood cell status tests or liver function tests) or urine tests (for glucose), let the doctor or nurse know that they are taking Curam 312.5 mg/5 ml. This is because Curam 312.5 mg/5 ml can affect the results of these types of tests.</p><p><strong>Other medicines and </strong>Curam 312.5 mg/5 ml</p><p>Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines. This includes medicines that can be bought without a prescription and herbal medicines.</p><p>If your child is taking <strong>allopurinol </strong>(used for gout) with Curam 312.5 mg/5 ml, it may be more likely that they will have an allergic skin reaction</p><p>&nbsp;</p><p>&nbsp;</p><p>If your child is taking <strong>probenecid </strong>(used for gout), your doctor may decide to adjust your dose of Curam 312.5 mg/5 ml.</p><p>If medicines to help stop blood clots (such as <strong>warfarin</strong>) are taken with Curam 312.5 mg/5 ml then extra blood tests may be needed.</p><p>Curam 312.5 mg/5 ml can affect how <strong>methotrexate </strong>(a medicine used to treat cancer or rheumatic diseases) works.</p><p>Curam 312.5 mg/5 ml may affect how <strong>mycophenolate mofetil </strong>(a medicine used to prevent the rejection of transplanted organs) works.</p><p><strong>Pregnancy, breast-feeding and fertility:</strong></p><p>If your child who is about to take this medicine is pregnant or breast-feeding, thinks it may be pregnant or is planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines:</strong></p><p>Curam 312.5 mg/5 ml can have side effects and the symptoms may make you unfit to drive. Do not drive or operate machinery unless you are feeling well.</p><p>This medicine contains 8.5 mg aspartame in each dosage unit. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.</p><p>This medicine contains 0,56 mg benzyl alcohol in each dosage unit. Benzyl alcohol may cause allergic reactions. Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always give this medicine exactly as your doctor has told you. Check with your doctor or pharmacist, if you are not sure.</p><p><strong>Adults and children weighing 40 kg and over</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This suspension is not usually recommended for adults and children weighing 40 kg and over. Ask your doctor or pharmacist for advice.</p><p><strong>Children weighing less than 40 kg</strong></p><p>All doses are worked out depending on the child&rsquo;s bodyweight in kilograms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will advise you how much Curam 312.5 mg/5 ml you should give to your baby or child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be provided with a plastic measuring spoon or syringe doser. You should use this to give the correct dose to your baby or child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose &ndash; 20 mg/5 mg to 60 mg/15 mg for each kilogram of body weight a day, given in three divided doses.</p><p><strong>Patients with kidney and liver problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child has kidney problems the dose might be changed. A different strength or a different medicine may be chosen by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child has liver problems they may have more frequent blood tests to check how their liver is working.</p><p><strong>How to give Curam 312.5 mg/5 ml </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always shake the bottle well before each dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Give with a meal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Space the doses evenly during the day, at least 4 hours apart. Do not take 2 doses in 1 hour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not give your child Curam 312.5 mg/5 ml for more than 2 weeks. If your child still feels unwell they should go back to see the doctor.</p><p><strong>If you give more Curam 312.5 mg/5 ml than you should</strong></p><p>If you give your child too much Curam 312.5 mg/5 ml, signs might include an upset stomach (feeling sick, being sick or diarrhoea) or convulsions. Talk to their doctor as soon as possible. Take the medicine bottle to show the doctor.</p><p><strong>If you forget to give Curam 312.5 mg/5 ml </strong></p><p>If you forget to give your child a dose, give it as soon as you remember. You should not give your child the next dose too soon, but wait about 4 hours before giving the next dose. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If your child stops taking Curam 312.5 mg/5 ml </strong></p><p>Keep giving your child Curam 312.5 mg/5 ml until the treatment is finished, even if they feel better. Your child needs every dose to help fight the infection. If some bacteria survive they can cause the infection to come back.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Conditions you need to look out for Allergic reactions:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels (<em>vasculitis</em>) which may be visible as red or purple raised spots on the skin, but can affect other parts of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, joint pain, swollen glands in the neck, armpit or groin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or throat (<em>angioedema</em>), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse.</p><p><strong>Contact a doctor immediately </strong>if your child gets any of these symptoms. <strong>Stop taking Curam 312.5 mg/5 ml.</strong></p><p><strong>Inflammation of large intestine</strong></p><p>Inflammation of the large intestine, causing watery diarrhoea usually with blood and mucus, stomach pain and/or fever.</p><p><strong>Contact your doctor as soon as possible </strong>for advice if your child gets these symptoms.</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (in adults).</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrush (<em>candida </em>- a yeast infection of the vagina, mouth or skin folds)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), especially when taking high doses. If affected take Curam 312.5 mg/5 ml with a meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (in children).</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised itchy rash (<em>hives</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p>&nbsp;</p><p>Uncommon side effects that may show up in your blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in some substances (<em>enzymes</em>) produced by the liver</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge &ndash; <em>erythema multiforme)</em></p><p>if you notice any of these symptoms contact a doctor urgently.</p><p>Rare side effects that may show up in your blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of cells involved in blood clotting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells</p><p><strong>Frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>Other side effects have occurred in a very small number of people but their exact frequency is unknown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (see above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the large intestine (see above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the protective membrane surrounding the brain (<em>aseptic meningitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin reactions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose eyes and genitals (<em>Stevens-Johnson syndrome</em>), and a more severe form, causing extensive peeling of the skin (more than 30% of the body surface &ndash; <em>toxic epidermal necrolysis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widespread red skin rash with small pus-containing blisters (<em>bullous exfoliative dermatitis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red, scaly rash with bumps under the skin and blisters (<em>exanthemous pustulosis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms with a rash, fever, swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes) (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS))</p><p><strong>Contact a doctor immediately if your child gets any of these symptoms.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice, caused by increases in the blood of bilirubin (a substance produced in the liver) which may make your child&rsquo;s skin and whites of the eyes appear yellow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of tubes in the kidney</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood takes longer to clot</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions (in people taking high doses of Curam 312.5 mg/5 ml or who have kidney problems)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; black tongue which looks hairy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stained teeth (in children), usually removed by brushing</p><p>Side effects that may show up in blood or urine tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe reduction in the number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of red blood cells (<em>haemolytic anaemia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crystals in urine.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of side effects</u></p><p>If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&ordm;C. Store in the original package, in order to protect from moisture. After preparation of the ready-to-use suspension:</p><p>Store in a refrigerator (2&deg; - 8 &deg;C) and use within 7 days.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are amoxicillin and clavulanic acid. Curam 312.5 mg/5 ml powder for oral suspension</p><p>5 ml reconstituted suspension contain 250 mg amoxicillin and 62.5 mg clavulanic acid.</p><p>- The other ingredients are: Citric acid, trisodium citrate, aspartame (E951), talc, guar, silicon dioxide, lemon flavouring (contains sorbitol and glucose), peach-apricot flavouring (contains sorbitol) and orange flavouring (contains benzyl alcohol)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Curam 312.5 mg/5 ml is an off-white powder.
After reconstitution the ready-for-use suspension is off-white.
Content of the pack:
-	Amber glass bottle, 60 ml, 100 ml respectively 120 ml with ring mark
-	Screw closure with sealing membranes
-	Measuring spoon (5 ml) made of polypropylene or measuring syringe (5 ml) with adapter made of polyethylene/polypropylene.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sandoz GmbH</p><p>Biochemiestrasse 10</p><p>6250 Kundl</p><p>Austria<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">عقار كيورام 312.5 مجم/5 مللي لتر عبارة عن مضاد حيوي ويعمل عن طريق قتل البكتيريا التي تسبب العدوى. فهو يحتوي على دواءين مختلفين يُطلق عليهما أموكسيسيلين وحمض الكلافيولانيك. ينتمي أموكسيسيلين إلى مجموعة من الأدوية تُسمى &quot;البنسيلينات&quot; والتي يمكن إيقافها في بعض الأحيان عن العمل (تكون غير نشطة). يعمل المكون النشط الآخر (حمض الكلافيولانيك) على إيقاف حدوث ذلك.</p><p dir="RTL">يُستخدم عقار كيورام 312.5 مجم/5 مللي لتر في البالغين والأطفال لعلاج العدوى الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأذن الوسطى والجيوب الأنفية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التَّنفسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز البولي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة بما في ذلك عدوى الأسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى العظام والمفاصل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تعطِ طفلك عقار كيورام&nbsp; </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر في الحالات الآتية</strong><strong>: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يعاني من حساسية تجاه أموكسيسيلين، حمض الكلافيولانيك، البنسيلين أو تجاه أيٍّ من المكونات الأخرى الموجودة بهذا الدَّواء (المدرجة في القسم: 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد أصيب من قبل بتفاعل حساسية شديد تجاه أي مضاد حيوي آخر. من الممكن أن يشمل ذلك طفحًا جلديًّا أو تورمًا في الوجه أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد عانى من قبل من مشاكل بالكبد أو يرقان (اصفرار الجلد) عند تناول أحد المضادات الحيوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تعطِ عقار كيورام&nbsp; </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر لطفلك إذا كانت أي من الحالات السَّابقة تنطبق على طفلك</strong><strong>.&nbsp; </strong>إذا لم تكن متأكدًا، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل إعطاء عقار كيورام 312.5 مجم/5 مللي لتر.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><strong>:</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل إعطاء هذا الدَّواء لطفلك في الحالات التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان مُصابًا بالحمى الغُدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يخضع لعلاج مشاكل الكبد أو الكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لا يتبول بشكل منتظم.</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق على طفلك أيٌّ من الحالات السابقة، فتحدَّث إلى طبيبه أو الصيدلي الخاص به قبل إعطاء عقار كيورام 312.5 مجم/5 مللي لتر.</p><p dir="RTL">في بعض الحالات، قد يتحقق طبيبك من نوع البكتيريا التي تسبب العدوى لطفلك. اعتمادًا على النتائج، قد يتم إعطاء طفلك تركيزًا مختلفًا من عقار كيورام 312.5 مجم/5 مللي لتر أو دواء مختلف.</p><p dir="RTL"><strong>الحالات التي تحتاج إلى البحث عنها</strong></p><p dir="RTL">بإمكان عقار كيورام 312.5 مجم/5 مللي لتر أن يجعل بعض الحالات الموجودة بالفعل تتفاقم، أو يسبب آثارًا جانبية خطيرة. يشمل ذلك تفاعلات الحساسية، اختلاجات (تشنجات) والتهاب الأمعاء الغليظة. يجب البحث عن الإصابة ببعض الأعراض أثناء تناول طفلك عقار كيورام 312.5 مجم/5 مللي لتر، لتقليل خطر حدوث أي مشاكل. انظر<strong>&nbsp; </strong><em>&quot;</em><em>الحالات التي تحتاج إلى البحث عنها</em><em>&quot; </em>في <strong>القسم </strong><strong>4.</strong></p><p dir="RTL"><strong>اختبارات الدَّم والبول</strong></p><p dir="RTL">إذا كان طفلك يخضع لاختبارات الدَّم (مثل: اختبارات حالة خلايا الدَّم الحمراء أو اختبارات وظائف الكبد) أو اختبارات البول (للجلوكوز)، فأخبر الطبيب أو الممرض(ة) أنه يتناول عقار كيورام 312.5 مجم/5 مللي لتر. هذا لأنَّ عقار كيورام 312.5 مجم/5 مللي لتر من الممكن أن يُؤثر&nbsp; على نتائج هذه الأنواع من الاختبارات.</p><p dir="RTL"><strong>الأدوية الأخرى</strong> وعقار كيورام 312.5 مجم/5 مللي لتر</p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي الخاص بك إذا كان طفلك يتناول، أو تناول مؤخرًا أو قد يتناول أيَّة أدوية أخرى. يشمل ذلك الأدوية التي يمكن شراؤها بدون وصفة طبية والأدوية العشبية.</p><p dir="RTL">إذا كان طفلك يتناول <strong>ألوبيرينول</strong> (يُستخدم لعلاج مرض النقرس) مع عقار كيورام 312.5 مجم/5 مللي لتر، فمن المرجح أن يُصاب بأحد تفاعلات الحساسية بالجلد.</p><p dir="RTL">إذا كان طفلك يتناول <strong>بروبينسيد</strong> (يُستخدم لعلاج مرض النقرس)، فقد يقرر طبيبك تعديل الجرعة من عقار كيورام 312.5 مجم/5 مللي لتر.</p><p dir="RTL">إذا تم تناول أدوية للمساعدة في وقف جلطات الدَّم (مثل <strong>وارفارين</strong>) مع عقار كيورام 312.5 مجم/5 مللي لتر، فقد يكون هناك حاجة إلى إجراء اختبارات دم إضافية.</p><p dir="RTL">من الممكن أن يُؤثر عقار كيورام 312.5 مجم/5 مللي لتر على كيفية عمل <strong>ميثوتريكسات</strong> (دواء يُستخدم لعلاج السرطان أو الأمراض الروماتيزمية).</p><p dir="RTL">قد يُؤثر عقار كيورام 312.5 مجم/5 مللي لتر على كيفية عمل <strong>ميكوفينولات موفيتيل</strong> (دواء يُستخدم لمنع رفض الأعضاء المزروعة).</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong><strong>:</strong></p><p dir="RTL">إذا كانت طفلتك التي على وشك تناوُل هذا الدواء حاملًا أو مرضعًا، أو تعتقد أنها حامل أو تخطط للحمل، فاستشر طبيبك أو الصيدلي الخاص بك قبل تناول هذا الدَّواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><strong>:</strong></p><p dir="RTL">من الممكن أن يسبب عقار كيورام 312.5 مجم/5 مللي لتر آثارًا جانبية وقد تجعلك الأعراض غير مؤهل لممارسة القيادة. تجنب ممارسة القيادة أو تشغيل الآلات ما لم تشعر بأنك على ما يرام.</p><p dir="RTL">يحتوي هذا الدَّواء على 8.5 مجم من الأسبرتام في كل وحدة للجرعة. يُعد الأسبرتام مصدرًا للفينيل ألانين. قد يكون أمرًا ضارًّا إذا كنت مصابًا ببيلة الفينيل كيتون، وهو اضطراب وراثي نادر يتراكم فيه الفينيل ألانين لأنَّ الجسم لا يستطيع إزالته بشكل صحيح.</p><p dir="RTL">يحتوي هذا الدَّواء على 0.56 مجم من الكحول البنزيلي في كل وحدة للجرعة. قد يسبب الكحول البنزيلي تفاعلات حساسية. استشر طبيبك أو الصيدلي الخاص بك إذا كان لديك مرض بالكبد أو الكلى. يرجع ذلك إلى أنَّ الكميات الكبيرة من الكحول البنزيلي يمكن أن تتراكم في جسمك وقد تسبب آثارًا جانبية (تسمى &quot;الحُماض الاستقلابي&quot;).</p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا المنتج الدَّوائي.</p><p>يحتوي هذا الدَّواء على أقل من 1 مللي مول صوديوم (23 مجم) في كل وحدة للجرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم بإعطاء هذا الدَّواء دائمًا كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من طريقة الإعطاء.</p><p dir="RTL"><strong>البالغون والأطفال ممن يبلغ وزنهم </strong><strong>40 </strong><strong>كجم وأكثر</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوصى عادة بإعطاء هذا المعلق للبالغين والأطفال ممن يبلغ وزنهم 40 كجم وأكثر. استشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL"><strong>الأطفال ممن يبلغ وزنهم أقل من </strong><strong>40 </strong><strong>كجم</strong></p><p dir="RTL">يتم وصف الجرعات اعتمادًا على وزن جسم الطفل بالكيلو جرامات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقدم لك طبيبك النصيحة بشأن كمية عقار كيورام 312.5 مجم/5 مللي لتر التي يجب إعطاؤها لرضيعك أو طفلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم تزويدك بملعقة قياس بلاستيكية أو سرنجة للجرعات. يجب عليك استخدام هذا لإعطاء الجرعة الصحيحة لرضيعك أو طفلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها - 20 مجم/5 مجم إلى 60 مجم/15 مجم لكل كجم من وزن الجسم في اليوم، يتم إعطاؤها على هيئة ثلاث جرعات مقسمة.</p><p dir="RTL"><strong>المرضى المصابون بمشاكل بالكُلى والكبد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يعاني من مشاكل بالكلى فقد يتم تغيير الجرعة. قد يختار طبيبك تركيزًا مختلفًا أو دواءً مختلفًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يعاني من مشاكل بالكبد فقد يخضع لإجراء اختبارات للدم بشكل أكثر تكرارًا للتَّحقق من كيفية عمل الكبد لديه.</p><p dir="RTL"><strong>كيفية إعطاء عقار كيورام </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم دائمًا برَج الزجاجة جيدًا قبل كل جرعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعط الجرعة مع تَناوُل إحدى الوجبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باعد بين تَناوُل الجرعات بالتساوي أثناء اليوم، بفاصل زمني يبلغ 4 ساعات على الأقل. لا تتناول جرعتين في ساعة واحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تعط طفلك عقار كيورام 312.5 مجم/5 مللي لتر لمدة تزيد عن أسبوعين. إذا كان طفلك لا يزال يشعر بأنه ليس على ما يُرام، فيجب عليه العودة لزيارة الطبيب.</p><p dir="RTL"><strong>إذا قمت بإعطاء كمية أكثر مما يجب من عقار كيورام </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر</strong></p><p dir="RTL">إذا قمت بإعطاء طفلك كمية كبيرة للغاية من عقار كيورام 312.5 مجم/5 مللي لتر، قد تشمل العلامات اضطرابًا بالمعدة (الشعور بإعياء، إعياء أو إِسْهالًا) أو تشنجات. تحدث إلى طبيبه في أسرع وقت ممكن.&nbsp; خذ زجاجة الدواء لإظهارها للطبيب.</p><p dir="RTL"><strong>إذا أغفلت إعطاء عقار كيورام </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر </strong></p><p dir="RTL">إذا أغفلت إعطاء طفلك إحدى الجرعات، فقم بإعطائها له بمجرد تذكرك. يجب ألا تعطِ طفلك الجرعة التالية في وقت مبكر للغاية، ولكن انتظر حوالي حوالي 4 ساعات قبل إعطاء الجرعة التَّالية. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>إذا توقف طفلك عن تناول عقار كيورام </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر </strong></p><p dir="RTL">استمر في إعطاء طفلك عقار كيورام 312.5 مجم/5 مللي لتر حتى انتهاء العلاج، حتى إذا كان يشعر بتحسُّن. يحتاج طفلك إلى كل جرعة للمساعدة في مكافحة العدوى. في حال بقاء بعض البكتيريا على قيد الحياة فيمكنها أن تسبب حدوث العدوى مرة أخرى.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>الحالات التي تحتاج فيها إلى البحث عن تفاعلات الحساسية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدَّموية الذي قد يكون ظاهرًا على هيئة بقع بارزة حمراء أو أرجوانية على الجلد، ولكن يمكن أن يُؤثر على أجزاء أخرى من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى، ألم بالمفاصل، تورم بالغدد في الرقبة، الإبط أو الإربية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، في بعض الأحيان في الوجه أو الحلق <em>(</em><em>وذمة وعائية</em><em>)</em>، مما يؤدي إلى صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط.</p><p dir="RTL"><strong>اتصل بالطبيب فورًا </strong>إذا تعرض طفلك للإصابة بأيٍّ من هذه الأعراض. <strong>توقف عن تناول عقار كيورام </strong><strong>312.5 </strong><strong>مجم</strong><strong>/5 </strong><strong>مللي لتر</strong><strong>.</strong></p><p dir="RTL"><strong>التهاب الأمعاء الغليظة</strong></p><p dir="RTL">التهاب الأمعاء الغليظة، مما يسبب الإسهال المائي الذي عادة ما يكون مصحوبًا بالدَّم والمخاط، ألم بالمعدة و/ أو الحمى.</p><p dir="RTL"><strong>اتصل بطبيبك في أسرع وقت ممكن؛ </strong>للحصول على المشورة إذا تعرض طفلك للإصابة بهذه الأعراض.</p><p dir="RTL"><strong>آثار جانبية شائعة جدًّا</strong> (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال (في البالغين).</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السُّلاق (<em>داء</em> <em>المبيضات</em> &ndash; إحدى عدوى الخميرة التي تصيب المهبل أو الفم أو طيات الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بإعياء (غثيان)، خاصة عند تناوُل جرعات مرتفعة. إذا حدثت إصابة، فتناوَل عقار كيورام 312.5 مجم/5 مللي لتر مع تَناوُل إحدى الوجبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال (في الأطفال).</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بارز مصحوب بحكة <em>(</em><em>شرى </em><em>(</em><em>أرتكاريا</em><em>))</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير الشائعة التي قد تظهر في اختبارات الدَّم الخاصة بك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في بعض المواد (<em>الإنزيمات</em><em>)</em> التي يفرزها الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>طفح جلدي، والذي قد يظهر على هيئة بثور، ويبدو وكأنه بقع صغيرة (بقع داكنة مركزية تحيط بها منطقة شاحبة، مع وجود حلقة داكنة حول الحافة - <em>حُمامى عديدة الأشكال</em>).</p><p dir="RTL">إذا لاحظت أيًّا من هذه الأعراض، فاتصل بالطبيب بسرعة.</p><p dir="RTL">الآثار الجانبية النَّادرة التي قد تظهر في اختبارات الدَّم الخاصة بك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الخلايا المشاركة في تجلط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم البيضاء</p><p dir="RTL"><strong>معدل التكرار غير معروف</strong> (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">حدثت آثار جانبية أخرى في عدد قليل جدًّا من الأشخاص ولكن معدل تكرارها الدَّقيق غير معروف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (انظر أعلاه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة (انظر أعلاه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء الواقي المحيط بالمخ (<em>التهاب السحايا العقيم</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّفاعلات الجلدية الخطيرة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار مع بثور وتقشر الجلد، خاصة حول الفم، والأنف والعينين والأعضاء التناسلية (<em>متلازمة ستيفنز </em><em>- </em><em>جونسون</em>)، والشكل الأكثر شدة، يسبب تقشرًا واسع النطاق للجلد (أكثر من 30٪ من سطح الجسم - <em>انحلال البشرة النخري التسممي</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر واسع الانتشار مع بثور صغيرة تحتوي على صديد (<em>التهاب الجلد التقشري الفقاعي</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر متقشر مع نتوءات تحت الجلد وبثور (<em>البُثار الطفحي</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بأعراض الأنفلونزا مع طفح جلدي، حمى، تورم بالغدد، ونتائج غير طبيعية باختبار الدَّم (بما في ذلك زيادة خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات) وأنزيمات الكبد) (التَّفاعل الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية).</p><p dir="RTL"><strong>اتصل بالطبيب فورًا إذا تعرض طفلك للإصابة بأيٍّ من هذه الأعراض</strong><strong>.</strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان، ناجم عن ارتفاعات البيليروبين بالدم (مادة يتم إفرازها في الكبد) مما قد يجعل الجلد وبياض العينين لدى طفلك يبدو أصفر اللون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنابيب بالكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استغراق الدم وقتًا أطول ليتجلط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النَّشاط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلاجات (في الأشخاص الذين يتناولون جرعات مرتفعة من عقار كيورام 312.5 مجم/5 مللي لتر ممن لديهم مشاكل بالكلى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لسان أسود يبدو به شعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَلْوُّنُ الأَسْنان (عند الأطفال)، عادة ما يتم إزالته عن طريق غسلها بالفرشاة</p><p dir="RTL">الآثار الجانبية التي قد تظهر في اختبارات الدَّم أو البول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في عدد خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم الحمراء (<em>فقر الدم الانحلالي</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود بلورات بالبول.</p><p dir="RTL"><u>الإبلاغ عن الآثار الجانبية</u></p><p>إذا تعرض طفلك لأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والزجاجة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا يخزن في درجة حرارة تتعدى 30 درجة مئوية. يخزن داخل العبوة الأصلية لحمايته من الرطوبة. بعد إعداد المعلق الجاهز للاستخدام:</p><p dir="RTL">يُخزن في الثلاجة في درجة حرارة تتراوح بين (2 - 8 درجة مئوية) ويُستخدم في غضون 7 أيام.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي أموكسيسيلين وحمض الكلافيولانيك. عقار كيورام 312.5 مجم/5 مللي لتر مسحوق لإعداد معلق فموي كل 5 مللي لتر من المعلق الذي تم إعداده تحتوي على 250 مجم أموكسيسيلين و 62.5 مجم حمض الكلافيولانيك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: حمض الستريك، سترات ثلاثي الصوديوم، أسبارتام (E951)، تلك، صمغ الغوار، ثاني أكسيد السيليكون، نكهة الليمون (تحتوي على السوربيتول والجلوكوز)، نكهة الخوخ - المشمش (تحتوي على السوربيتول) ونكهة البرتقال (تحتوي على الكحول البنزيلي).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار كيورام 312.5 مجم/5 مللي لتر عبارة عن مسحوق أبيض يميل إلى الاصفرار.</p><p dir="RTL">بعد الإعداد، يكون المعلق الجاهز للاستخدام أبيض يميل إلى الاصفرار.</p><p dir="RTL"><strong>محتوى العبوة</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة زجاجية كهرمانية اللون بحجم 60 مللي لتر، 100 مللي لتر على التوالي، 120 مللي لتر مزودة بعلامة حلقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غطاء لولبي مع غشاء محكم</p><p>ملعقة قياس (5 مللي لتر) مصنوعة من البولي بروبيلين أو سرنجة قياس (5 مللي لتر) مع موائم مصنوعة من البولي إيثيلين/ البولي بروبيلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة ساندوز المحدودة</p><p dir="RTL">بايوكيميستراس 10</p><p dir="RTL">6250 كوندل</p><p dir="RTL">النمسا<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2020/04
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Curam 312.5 mg / 5 ml powder for oral suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml reconstituted suspension (corresponding to 0.125 g powder) contains 50 mg amoxicillin (as amoxicillin trihydrate) and 12.5 mg clavulanic acid (as potassium clavulanate).

Excipients with known effect:

Each ml reconstituted suspension (corresponding to 0.125 g powder) contains 1.7 mg aspartame. Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.019 mmol (0.44 mg) sodium.
Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.21 mg glucose.     Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.03 mg sorbitol.     Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.11 mg benzyl alcohol.


For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for oral suspension Off-white powder. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Curam is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial sinusitis (adequately diagnosed)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute otitis media</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community acquired pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cystitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyelonephritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone and joint infections, in particular osteomyelitis.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.</p><p>&nbsp;</p><p>The dose of Curam that is selected to treat an individual infection should take into account:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The severity and the site of the infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The age, weight and renal function of the patient as shown below.</p><p>&nbsp;</p><p>The use of alternative presentations of Curam (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>For adults and children  40 kg, this formulation of Curam provides a total daily dose of 1500 mg amoxicillin/375 mg clavulanic acid, when administered as recommended below. For children &lt; 40 kg, this formulation of Curam provides a maximum daily dose of 2400 mg amoxicillin/600 mg clavulanic acid, when administered as recommended below. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that another</p><p>&nbsp;</p><p>preparation of Curam is selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review (see section 4.4 regarding prolonged therapy).</p><p>&nbsp;</p><p>Adults and children  40 kg</p><p>One 500 mg/125 mg dose taken three times a day.</p><p>&nbsp;</p><p>Children &lt; 40 kg</p><p>20 mg/5 mg/kg/day to 60 mg/15 mg/kg/day given in three divided doses.</p><p>&nbsp;</p><p>Children may be treated with Curam tablets, suspensions or paediatric sachets. Children aged 6 years and below should preferably be treated with Curam suspension or paediatric sachets.</p><p>&nbsp;</p><p>No clinical data are available on doses of Curam 4:1 formulations higher than 40 mg/10 mg/kg per day in children under 2 years.</p><p>&nbsp;</p><p>Elderly</p><p>No dose adjustment is considered necessary.</p><p>&nbsp;</p><p>Renal impairment</p><p>Dose adjustments are based on the maximum recommended level of amoxicillin.</p><p>No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.</p><p>&nbsp;</p><p>Adults and children  40 kg</p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CrCl: 10-30</p><p>ml/min</p></td><td style="vertical-align:top"><p>500 mg/125 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>CrCl &lt; 10 ml</p><p>/min</p></td><td style="vertical-align:top"><p>500 mg/125 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>500 mg/125 mg every 24 hours, plus 500 mg/125 mg during dialysis, to be repeated at the end of dialysis (as serum concentrations of both amoxicillin and clavulanic acid are decreased)</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Children &lt; 40 kg</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CrCl: 10-30</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg twice daily (maximum 500 mg/125 mg twice daily).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>ml/min</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CrCl &lt; 10 ml</p><p>/min</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg as a single daily dose (maximum 500 mg/125 mg).</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg per day once daily.</p><p>Prior to haemodialysis 15 mg/3.75 mg/kg. In order to restore circulating drug levels, 15 mg/3.75 mg per kg should be administered after haemodialysis.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><u>Hepatic impairment</u></p><p>Dose with caution and monitor hepatic function at regular intervals (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Curam is for oral use.</p><p>&nbsp;</p><p>Curam should be administered with a meal to minimise potential gastrointestinal intolerance.</p><p>&nbsp;</p><p>Therapy can be started parenterally according the SPC of the IV-formulation and continued with an oral preparation.</p><p>&nbsp;</p><p>Shake to loosen powder, add water as directed, invert and shake. Shake the bottle before each dose (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients listed in section 6.1.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid (see section 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.</p><p>&nbsp;</p><p>In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.</p><p>&nbsp;</p><p>This presentation of Curam is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid.&nbsp; This presentation should not be used to treat penicillin-resistant <em>S. pneumoniae</em>.</p><p>&nbsp;</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses (see section 4.8).</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.</p><p>&nbsp;</p><p>Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.</p><p>&nbsp;</p><p>Prolonged use may occasionally result in overgrowth of non-susceptible organisms.</p><p>&nbsp;</p><p>The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP) (see Section 4.8). This reaction requires Curam discontinuation and contra-indicates any subsequent administration of amoxicillin.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment (see sections 4.2, 4.3 and 4.8).</p><p>&nbsp;</p><p>Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment.&nbsp; These events have been very rarely reported in children.&nbsp; In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and, in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects (see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Antibiotic-associated colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening (see section 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contra-indicated in this situation.</p><p>&nbsp;</p><p>Periodic assessment of organ system functions, including renal, hepatic and haematopoietic function is advisable during prolonged therapy.</p><p>&nbsp;</p><p>Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see section 4.5 and 4.8).</p><p>&nbsp;</p><p>In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see section 4.2).</p><p>&nbsp;</p><p>In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see section 4.9).</p><p>&nbsp;</p><p>During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non- enzymatic methods.</p><p>&nbsp;</p><p>The presence of Clavulanic acid in Curam may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.</p><p>&nbsp;</p><p>There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.</p><p>&nbsp;</p><p>Curam contains 1.7 mg of aspartame (E951) per ml, a source of phenylalanine. This medicine should be used with caution in patients with phenylketonuria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Oral anticoagulants</u></p><p>Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co- administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</p><p>&nbsp;</p><p><u>Probenecid</u></p><p>Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.</p><p>&nbsp;</p><p><u>Mycophenolate mofetil</u></p><p>In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure.</p><p>Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Breast-feeding</u></p><p>Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. The possibility</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>of sensitisation should be taken into account. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.</p><p>&nbsp;</p><p>The ADRs derived from clinical studies and post-marketing surveillance with Curam, sorted by MedDRA System Organ Class are listed below.</p><p>&nbsp;</p><p>The following terminologies have been used in order to classify the occurrence of undesirable effects. Very common (&sup3;1/10)</p><p>Common (&sup3;1/100 to &lt;1/10) Uncommon (&sup3;1/1,000 to &lt;1/100) Rare (&sup3;1/10,000 to &lt;1/1,000) Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mucocutaneous candidosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Overgrowth of non-susceptible organisms</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Reversible leucopenia (including neutropenia)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Reversible agranulocytosis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Prolongation of bleeding time and prothrombin time1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong><strong>10</strong></p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylaxis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Serum sickness-like syndrome</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity vasculitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reversible hyperactivity</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions2</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Aseptic meningitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea3</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Indigestion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Antibiotic-associated colitis4</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Black hairy tongue</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Tooth discolouration11</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rises in AST and/or ALT5</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis6</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Cholestatic jaundice6</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong>7</p></td></tr><tr><td style="vertical-align:top"><p>Skin rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Bullous exfoliative-dermatitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Acute generalised exanthemous pustulosis (AGEP)9</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Crystalluria8</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>1&nbsp; See section 4.4</p><p>2&nbsp; See section 4.4</p><p>3&nbsp; Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking Curam with a meal.</p><p>4&nbsp; Including pseudomembranous colitis and haemorrhagic colitis (see section 4.4)</p><p>5&nbsp; A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown.</p><p>6&nbsp;&nbsp; These events have been noted with other penicillins and cephalosporins (see section 4.4).</p><p>7&nbsp; If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued (see section 4.4).</p><p>8&nbsp; See section 4.9</p><p>9&nbsp; See section 4.4</p><p>10&nbsp; See sections 4.3 and 4.4</p><p>11&nbsp; Superficial tooth discolouration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs of overdose</u></p><p>Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see section 4.4).</p><p>&nbsp;</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses.</p><p>&nbsp;</p><p>Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses.&nbsp; A regular check of patency should be maintained (see section 4.4).</p><p>&nbsp;</p><p><u>Treatment of intoxication</u></p><p>Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CR02.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.</p><p>&nbsp;</p><p>Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.</p><p>&nbsp;</p><p>Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.</p><p>&nbsp;</p><p><u>PK/PD relationship</u></p><p>The time above the minimum inhibitory concentration (T&gt;MIC) is considered to be the major determinant of efficacy for amoxicillin.</p><p>&nbsp;</p><p><u>Mechanisms of resistance</u></p><p>The two main mechanisms of resistance to amoxicillin/clavulanic acid are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.</p><p>&nbsp;</p><p>Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>MIC breakpoints for amoxicillin/clavulanic acid are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Organism</p></td><td colspan="3" style="vertical-align:top"><p>Susceptibility Breakpoints (&micro;g/ml)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Intermediate</p></td><td style="vertical-align:top"><p>Resistant</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em><strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 1</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em><strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 1</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em><strong>2</strong></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci <strong>2</strong></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus</em><strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus A, B, C, G</em><strong>5</strong></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em><strong>3</strong></p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>1-2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriaceae<strong>1,4</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative Anaerobes<strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive Anaerobes<strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>4-8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>1&nbsp; The reported values are for Amoxicillin concentrations. For susceptibility testing purposes, the concentration of Clavulanic acid is fixed at 2 mg/l.</p><p>2&nbsp; The reported values are Oxacillin concentrations.</p><p>3&nbsp; Breakpoint values in the table are based on Ampicillin breakpoints.</p><p>4&nbsp; The resistant breakpoint of R&gt;8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.</p><p>5&nbsp; Breakpoint values in the table are based on Benzylpenicillin breakpoints.</p></td></tr></tbody></table><p>&nbsp;</p><p>The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p><!--[if gte vml 1]><o:wrapblock
 pagebreak="t">
 <v:group id="Group_x0020_12" o:spid="_x0000_s1034" style='position:absolute;
  margin-left:79.2pt;margin-top:12.45pt;width:464.9pt;height:68.9pt;z-index:1096;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1584,249" coordsize="9298,1378"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
">
  <v:line id="Line_x0020_19" o:spid="_x0000_s1035" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,271" to="10862,271"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_18" o:spid="_x0000_s1036" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,549" to="10862,549"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_17" o:spid="_x0000_s1037" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1595,260" to="1595,1616"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_16" o:spid="_x0000_s1038" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,1605" to="10862,1605"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_15" o:spid="_x0000_s1039" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="10871,260" to="10871,1616"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.08pt"/>
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_14" o:spid="_x0000_s1040"
   type="#_x0000_t202" style='position:absolute;left:1595;top:271;width:9276;
   height:279;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
   o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'>Commonly susceptible species<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_13" o:spid="_x0000_s1041" type="#_x0000_t202"
   style='position:absolute;left:1595;top:549;width:9276;height:1056;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'><u>Aerobic Gram-positive
      micro-organisms</u><o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.3pt;margin-right:5.0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:101%'><i
      style='mso-bidi-font-style:normal'>Enterococcus faecalis Gardnerella
      vaginalis<o:p></o:p></i></p>
      <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'><i style='mso-bidi-font-style:
      normal'>Staphylococcus aureus (</i>methicillin-susceptible)£<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="621" height="92" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci (methicillin-susceptible)</p><p><em>Streptococcus agalactiae Streptococcus pneumoniae</em>1</p><p><em>Streptococcus pyogenes </em>and other beta-haemolytic streptococci</p><p><em>Streptococcus viridans </em>group</p><p>&nbsp;</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Capnocytophaga </em>spp. <em>Eikenella corrodens Haemophilus influenzae</em>2 <em>Moraxella catarrhalis Pasteurella multocida</em></p><p>&nbsp;</p><p><u>Anaerobic micro-organisms </u><em>Bacteroides fragilis Fusobacterium nucleatum Prevotella </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p>Species for which acquired resistance may be a problem</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecium </em>$</p><p>&nbsp;</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Proteus vulgaris</em></p></td></tr><tr><td style="vertical-align:top"><p>Inherently resistant organisms</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter </em>sp. <em>Citrobacter freundii Enterobacter </em>sp.</p><p><em>Legionella pneumophila Morganella morganii Providencia </em>spp.</p><p><em>Pseudomonas </em>sp.</p><p><em>Serratia </em>sp.</p><p><em>Stenotrophomonas maltophilia</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_4" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:79.2pt;margin-top:15.5pt;width:464.9pt;height:172.6pt;z-index:1168;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1584,310" coordsize="9298,3452"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_11" o:spid="_x0000_s1027" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,332" to="10862,332"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_10" o:spid="_x0000_s1028" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,2166" to="10862,2166"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_9" o:spid="_x0000_s1029" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1595,321" to="1595,3751"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_8" o:spid="_x0000_s1030" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,3740" to="10862,3740"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_7" o:spid="_x0000_s1031" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="10871,321" to="10871,3751"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:shape id="Text_x0020_Box_x0020_6" o:spid="_x0000_s1032" type="#_x0000_t202"
   style='position:absolute;left:1595;top:332;width:9276;height:1834;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDWKgUqwgAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvwv6H8Ba8aaoH0a5RRFYQBLHWg8e3zbMNNi/dJmr990ZY2OMwM98w82Vna3Gn1hvHCkbDBARx
4bThUsEp3wymIHxA1lg7JgVP8rBcfPTmmGr34Izux1CKCGGfooIqhCaV0hcVWfRD1xBH7+JaiyHK
tpS6xUeE21qOk2QiLRqOCxU2tK6ouB5vVsHqzNm3+d3/HLJLZvJ8lvBuclWq/9mtvkAE6sJ/+K+9
1Qpm8L4Sb4BcvAAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDWKgUqwgAAANoAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.2pt'><span style='font-size:11.5pt;
      mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
      <p class=MsoNormal style='margin-top:0in;margin-right:333.15pt;
      margin-bottom:0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:
      101%'><u>Other micro-organisms </u><i style='mso-bidi-font-style:normal'>Chlamydophila
      pneumoniae Chlamydophila psittaci Coxiella burnetti Mycoplasma pneumoniae<o:p></o:p></i></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1033" type="#_x0000_t202"
   style='position:absolute;left:1595;top:2166;width:9276;height:1575;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'>$ Natural intermediate
      susceptibility in the absence of acquired mechanism of resistance.<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.3pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:12.15pt;
      mso-line-height-rule:exactly'>£All methicillin-resistant staphylococci
      are resistant to amoxicillin/clavulanic acid<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.65pt;margin-right:8.25pt;
      margin-bottom:0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:
      13.0pt;mso-line-height-rule:exactly'><span style='font-size:7.0pt;
      mso-bidi-font-size:11.0pt;position:relative;top:-5.0pt;mso-text-raise:
      5.0pt'>1</span><i style='mso-bidi-font-style:normal'>Streptococcus
      pneumoniae </i>that are resistant to penicillin should not be treated
      with this presentation of amoxicillin/clavulanic acid (see sections 4.2
      and 4.4).<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:0in;margin-right:8.25pt;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:13.0pt;
      mso-line-height-rule:exactly'><span style='font-size:7.0pt;mso-bidi-font-size:
      11.0pt;position:relative;top:-5.0pt;mso-text-raise:5.0pt'>2 </span>Strains
      with decreased susceptibility have been reported in some countries in the
      EU with a frequency higher than 10%.<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:621.396px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:620.604px"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Other micro-organisms </u><em>Chlamydophila pneumoniae Chlamydophila psittaci Coxiella burnetti Mycoplasma pneumoniae</em></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>$ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.</p><p>&pound;All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid</p><p>1<em>Streptococcus pneumoniae </em>that are resistant to penicillin should not be treated with this presentation of amoxicillin/clavulanic acid (see sections 4.2 and 4.4).</p><p>2 Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Amoxicillin and clavulanic acid, are fully dissociated in aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral route of administration. Absorption of amoxicillin/clavulanic acid is optimised when taken at the start of a meal. Following oral administration, amoxicillin and clavulanic acid are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (Tmax) in each case is approximately one hour.</p><p>&nbsp;</p><p>The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (500 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers are presented below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Mean (&plusmn; SD) pharmacokinetic parameters</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Active substance(s) administered</p></td><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>Tmax *</p></td><td style="vertical-align:top"><p>AUC (0-24h)</p></td><td style="vertical-align:top"><p>T 1/2</p></td></tr><tr><td style="vertical-align:top"><p>(mg)</p></td><td style="vertical-align:top"><p>(&micro;g/ml)</p></td><td style="vertical-align:top"><p>(h)</p></td><td style="vertical-align:top"><p>(&micro;g.h/ml)</p></td><td style="vertical-align:top"><p>(h)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Amoxicillin</p></td></tr><tr><td style="vertical-align:top"><p>AMX/CA</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>7.19</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>53.5</p></td><td style="vertical-align:top"><p>1.15</p></td></tr><tr><td style="vertical-align:top"><p>500/125 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&plusmn; 2.26</p></td><td style="vertical-align:top"><p>(1.0-2.5)</p></td><td style="vertical-align:top"><p>&plusmn; 8.87</p></td><td style="vertical-align:top"><p>&plusmn; 0.20</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Clavulanic acid</p></td></tr><tr><td style="vertical-align:top"><p>AMX/CA</p><p>500 mg/125 mg</p></td><td style="vertical-align:top"><p>125</p></td><td style="vertical-align:top"><p>2.40</p><p>&plusmn; 0.83</p></td><td style="vertical-align:top"><p>1.5</p><p>(1.0-2.0)</p></td><td style="vertical-align:top"><p>15.72 &plusmn; 3.86</p></td><td style="vertical-align:top"><p>0.98 &plusmn;</p><p>0.12</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:108.05pt;
  margin-top:16.6pt;width:371.9pt;height:28.45pt;z-index:1192;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1.08pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:4.8pt;line-height:12.6pt;
     mso-line-height-rule:exactly'>AMX – amoxicillin, CA – clavulanic acid<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.3pt;margin-right:0in;margin-bottom:
     0in;margin-left:4.8pt;margin-bottom:.0001pt'>* Median (range)<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="500" height="43" alt="Text Box: AMX – amoxicillin, CA – clavulanic acid
* Median (range)
" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid.</p><p>&nbsp;</p><p>Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus.</p><p>Amoxicillin does not adequately distribute into the cerebrospinal fluid.</p><p>&nbsp;</p><p>From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk (see section 4.6).</p><p>Both amoxicillin and clavulanic acid have been shown to cross the placental barrier (see section 4.6). <u>Biotransformation</u></p><p>Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to</p><p>up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of single Curam 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid (see section 4.5).</p><p>&nbsp;</p><p><u>Age</u></p><p>The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted <em>via </em>the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.</p><p>&nbsp;</p><p>Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.</p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with Curam or its components.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid Trisodium citrate</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Aspartame (E951) Talc</p><p>Guar</p><p>Silicon dioxide</p><p>Lemon flavouring (contains glucose and sorbitol) Peach-apricot flavouring (contains sorbitol) Orange flavouring (contains benzyl alcohol)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
The reconstituted suspension is stable for 7 days when stored at 2-8 °C

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder for oral suspension: Do not store above 30&deg;C. Store in the original package, in order to&nbsp; protect from moisture.</p><p>The reconstituted suspension should be stored in a refrigerator (2&deg; - 8 &deg;C) and used within 7 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Curam 312.5 mg/5 ml powder for oral suspension The primary packaging materials consists of</p><p>-&nbsp; Amber glass bottle, 60 ml, 100 ml respectively 120 ml with ring mark</p><p>-&nbsp; Screw closure with sealing membranes</p><p>-&nbsp; Measuring spoon (5 ml) made of polypropylene or measuring syringe (5 ml) with adapter made of polyethylene/polypropylene.</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:85.1pt;margin-top:14.45pt;
  width:280.45pt;height:77.9pt;z-index:1216;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="silver" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05pt'>2 bottles of 9.38 g powder
     (for preparing 2 x 75 ml suspension)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.3pt;margin-right:2.5pt;margin-bottom:
     0in;margin-left:0in;margin-bottom:.0001pt;line-height:101%'>2 bottles of
     7.5 g powder (for preparing 2 x 60 ml suspension) 1 bottle of 12.5 g
     powder (for preparing 100 ml suspension)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:17.8pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;line-height:101%'>1
     bottle of 9.38 g powder (for preparing 75 ml suspension) 1 bottle of 7.5 g
     powder (for preparing 60 ml suspension)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05pt'>1 bottle of 15.0 g powder
     (for preparing 120 ml suspension)<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="377" height="107" alt="Text Box: 2 bottles of 9.38 g powder (for preparing 2 x 75 ml suspension)
2 bottles of 7.5 g powder (for preparing 2 x 60 ml suspension) 1 bottle of 12.5 g powder (for preparing 100 ml suspension)
1 bottle of 9.38 g powder (for preparing 75 ml suspension) 1 bottle of 7.5 g powder (for preparing 60 ml suspension)
1 bottle of 15.0 g powder (for preparing 120 ml suspension)
" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Check cap seal is intact before using. Shake bottle to loosen powder. Add volume of water (as indicated below) invert and shake well. Alternatively fill the bottle with water to just below the mark on bottle label, invert and shake well, then top up with water exactly to the mark, invert and again shake well.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Strength</strong></p></td><td style="vertical-align:top"><p><strong>Volume of water to be added at reconstitution (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Final volume of reconstituted oral suspension (ml)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>125 mg/31.25 mg/5 ml</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>71.25</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>114</p></td><td style="vertical-align:top"><p>120</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>250 mg/62.5 mg/5 ml</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>67.5</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>120</p></td></tr></tbody></table><p>&nbsp;</p><p>Shake the bottle well before each dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>After reconstitution the ready-for-use suspension is off-white.</p><p>&nbsp;</p><p>This medicinal product should not be used if lumps of powder are still visible in the bottle before reconstitution.</p><p>After reconstitution the product should not be used if the colour of the reconstituted product is different from the one described before.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH
Biochemiestrasse 10
6250 Kundl 
Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>